11 Results

People

  1. Lahoud
    Lahoud
  2. Giralt
    Giralt
  3. Landau
    Landau
  4. Chung
    Chung
  5. Shah
    Shah
  6. Hassoun
    Hassoun
  7. Korde
    Korde
  8. Lesokhin
    Lesokhin
  9. Mailankody
    Mailankody
  10. Scordo
    Scordo

Groups

  1. Department of Medicine (11)
  2. Hematologic Malignancies, Division of (11)
  3. Bone Marrow Transplant (9)
  4. Center for Hematologic Malignancies (9)
  5. Survivorship Research (9)
  6. Biostatistics Service (7)
  7. CTCR Scholars (7)
  8. Epidemiology and Biostatistics (7)
  9. Hematologic Malignancies Research (6)
  10. Myeloma (6)
  1. "male"
  2. "Oscar Lahoud"
Formats
  1. Journal Article (9)
  2. Correspondence (1)
  3. Research Letter (1)
Groups
  1. Department of Medicine (11)
  2. Hematologic Malignancies, Division of (11)
  3. Bone Marrow Transplant (9)
  4. Center for Hematologic Malignancies (9)
  5. Survivorship Research (9)
  6. Biostatistics Service (7)

More Groups

People
  1. Oscar Lahoud (11)
  2. Heather Landau (8)
  3. Sergio Giralt (8)
  4. David Chung (7)
  5. Gunjan Shah (7)
  6. Alexander Lesokhin (6)

More People

Years
  1. 2023 (5)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (1)
Publications
  1. Leukemia and Lymphoma (3)
  2. British Journal of Haematology (2)
  3. Biology of Blood and Marrow Transplantation (1)
  4. Blood Cancer Journal (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. Taylor & Francis Group (3)
  2. Elsevier Inc. (2)
  3. Elsevier Science, Inc. (2)
  4. John Wiley & Sons (2)
  5. American Medical Association (1)
  6. Nature Publishing Group (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma
    Journal Article

    Dahi, P. B.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Chinapen, S. A.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation
    Journal Article

    Elias, S.; Brown, S.; Devlin, S. M.; Barker, J. N.; Cho, C.; Chung, D. J.; Dahi, P. B.; Giralt, S.; Gyurkocza, B.; Jakubowski, A. A.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
    Journal Article

    Kubicki, T.; Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Robak, P.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Szczepaniak, T.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): Interim analysis of a randomised, open-label, phase 3 trial
    Journal Article

    Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Kubicki, T.; Robak, P.; Walter-Croneck, A.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: A case for response-adapted approach
    Journal Article

    Lahoud, O. B.; Landau, H.; Nguyen, J.; Devlin, S.; Lendvai, N.; Weltz, J.; Ayorinde, T.; Chung, D. J.; Lesokhin, A. M.; Kewalramani, T.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save